SEC Tracker
Get the app

Kura Oncology KURA

Kura Oncology reports strong Q3 2026 results

Kura Oncology (KURA) filed an 8-K with the SEC on Nov 10, 2026, 4:06 pm ET. Source: the filing on SEC EDGAR.

Item 2.02 Reports results

Form
8-K
Filed
Importance
Major
  1. KOMZIFTI net product revenue grew 53% to $13.9 million
  2. New patient starts increased 30% to 150
  3. Darlifarnib study in HRAS-mutated salivary gland cancer aligned with FDA
  4. Cash and investments totaled $492.1 million

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Kura Oncology files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.